Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01734928
Recruitment Status : Active, not recruiting
First Posted : November 28, 2012
Last Update Posted : May 10, 2021
Sponsor:
Information provided by (Responsible Party):
Celgene